Farnesyltransferase inhibitors

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

In the past year, clinical studies of the farnesyl transferase inhibitors (FTIs) have focused almost exclusively on hematologic malignancies, where efficacy continues to be demonstrated. In solid tumors, studies continue in breast cancer. These agents, which inhibit the post-translational modification of a large number of small G-proteins involved in cell signaling and cytoskeletal organization, are now known not to specifically inhibit Ras proteins. After over half a decade of clinical testing, the utility of these agents in the therapy of human malignancy remains to be defined. However, basic and translational studies over the past year have contributed to our understanding of the determinants of response to these agents, as well as mechanisms of resistance. With these insights, ongoing clinical studies will hopefully define the role of these agents in our anti-cancer armamentarium in the coming year.

Original languageEnglish (US)
Pages (from-to)17-23
Number of pages7
JournalUpdate on Cancer Therapeutics
Volume1
Issue number1
DOIs
StatePublished - Mar 1 2006

Fingerprint

Farnesyltranstransferase
ras Proteins
Neoplasms
Monomeric GTP-Binding Proteins
Hematologic Neoplasms
Post Translational Protein Processing
Transferases
Breast Neoplasms
Clinical Studies
Therapeutics

Keywords

  • Farnesyltransferase
  • G-proteins
  • HDJ-2
  • Lonafarnib
  • Prenylation
  • Ras
  • Rho
  • Tipifarnib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Farnesyltransferase inhibitors. / Adjei, Alex.

In: Update on Cancer Therapeutics, Vol. 1, No. 1, 01.03.2006, p. 17-23.

Research output: Contribution to journalReview article

@article{de9843f9add940f18da7738f79e18fbd,
title = "Farnesyltransferase inhibitors",
abstract = "In the past year, clinical studies of the farnesyl transferase inhibitors (FTIs) have focused almost exclusively on hematologic malignancies, where efficacy continues to be demonstrated. In solid tumors, studies continue in breast cancer. These agents, which inhibit the post-translational modification of a large number of small G-proteins involved in cell signaling and cytoskeletal organization, are now known not to specifically inhibit Ras proteins. After over half a decade of clinical testing, the utility of these agents in the therapy of human malignancy remains to be defined. However, basic and translational studies over the past year have contributed to our understanding of the determinants of response to these agents, as well as mechanisms of resistance. With these insights, ongoing clinical studies will hopefully define the role of these agents in our anti-cancer armamentarium in the coming year.",
keywords = "Farnesyltransferase, G-proteins, HDJ-2, Lonafarnib, Prenylation, Ras, Rho, Tipifarnib",
author = "Alex Adjei",
year = "2006",
month = "3",
day = "1",
doi = "10.1016/j.uct.2006.05.005",
language = "English (US)",
volume = "1",
pages = "17--23",
journal = "Update on Cancer Therapeutics",
issn = "1872-115X",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Farnesyltransferase inhibitors

AU - Adjei, Alex

PY - 2006/3/1

Y1 - 2006/3/1

N2 - In the past year, clinical studies of the farnesyl transferase inhibitors (FTIs) have focused almost exclusively on hematologic malignancies, where efficacy continues to be demonstrated. In solid tumors, studies continue in breast cancer. These agents, which inhibit the post-translational modification of a large number of small G-proteins involved in cell signaling and cytoskeletal organization, are now known not to specifically inhibit Ras proteins. After over half a decade of clinical testing, the utility of these agents in the therapy of human malignancy remains to be defined. However, basic and translational studies over the past year have contributed to our understanding of the determinants of response to these agents, as well as mechanisms of resistance. With these insights, ongoing clinical studies will hopefully define the role of these agents in our anti-cancer armamentarium in the coming year.

AB - In the past year, clinical studies of the farnesyl transferase inhibitors (FTIs) have focused almost exclusively on hematologic malignancies, where efficacy continues to be demonstrated. In solid tumors, studies continue in breast cancer. These agents, which inhibit the post-translational modification of a large number of small G-proteins involved in cell signaling and cytoskeletal organization, are now known not to specifically inhibit Ras proteins. After over half a decade of clinical testing, the utility of these agents in the therapy of human malignancy remains to be defined. However, basic and translational studies over the past year have contributed to our understanding of the determinants of response to these agents, as well as mechanisms of resistance. With these insights, ongoing clinical studies will hopefully define the role of these agents in our anti-cancer armamentarium in the coming year.

KW - Farnesyltransferase

KW - G-proteins

KW - HDJ-2

KW - Lonafarnib

KW - Prenylation

KW - Ras

KW - Rho

KW - Tipifarnib

UR - http://www.scopus.com/inward/record.url?scp=33746310371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746310371&partnerID=8YFLogxK

U2 - 10.1016/j.uct.2006.05.005

DO - 10.1016/j.uct.2006.05.005

M3 - Review article

AN - SCOPUS:33746310371

VL - 1

SP - 17

EP - 23

JO - Update on Cancer Therapeutics

JF - Update on Cancer Therapeutics

SN - 1872-115X

IS - 1

ER -